Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity‐modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

Abstract

The addition of bevacizumab and cetuximab to 2 cycles of cisplatin, given concurrently with IMRT, was well-tolerated and was associated with favorable efficacy outcomes in this patient population. © 2015 Wiley Periodicals, Inc. Head Neck 38: E566-E570, 2016.